股本结构
单位：万股
| 公告日期 | 2025-12-09 | 2025-10-09 | 2025-09-10 | 2025-08-01 | 2025-07-22 | 2025-05-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 380.16 | 380.16 | 313.99 | 313.99 | 289.64 | 80.10 |
| 普通股本 | 380.16 | 380.16 | 313.99 | 313.99 | 289.64 | 80.10 |
| 优先股 | 未披露 | 未披露 | 0.15 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-31 | 2025-10-08 | 2025-07-31 | 2025-07-30 | 2025-07-22 | 2025-05-12 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-12-09 | 380.16 | 未披露 |
更多>>
From July 31, 2025 to October 31, 2025
Conversion of preferred stock to common stock
|
2025-10-31 |
| 2025-10-09 | 380.16 | 未披露 | 定期报告 | 2025-10-08 |
| 2025-09-10 | 313.99 | 0.15 |
更多>>
From April 30, 2025 to July 31, 2025
Conversion of preferred stock to common stock
|
2025-07-31 |
| 2025-08-01 | 313.99 | 未披露 | 定期报告 | 2025-07-30 |
| 2025-07-22 | 289.64 | 未披露 | 定期报告 | 2025-07-22 |
| 2025-05-08 | 80.10 | 未披露 |
更多>>
a one-for-nine reverse stock split of Alzamend’s common stock
|
2025-05-12 |
| 2025-05-08 | 720.86 | 未披露 | 定期报告 | 2025-05-08 |
| 2025-03-27 | 660.86 | 未披露 | 定期报告 | 2025-03-26 |
| 2025-03-13 | 659.75 | 0.22 | 定期报告 | 2025-03-13 |
| 2025-03-10 | 659.75 | 未披露 | 定期报告 | 2025-03-07 |
| 2025-03-10 | 579.68 | 0.22 |
更多>>
From October 31, 2024 to January 31, 2025
Issuance of common stock for cash, net of issuance costs
|
2025-01-31 |
| 2024-12-11 | 543.28 | 未披露 | 定期报告 | 2024-12-10 |
| 2024-12-11 | 523.13 | 0.22 |
更多>>
From July 31, 2024 to October 31, 2024
Issuance of common stock for cash, net of issuance costs
Issuance of common stock for restricted stock awards
Conversion of preferred stock to common stock
|
2024-10-31 |
| 2024-10-03 | 447.54 | 未披露 | 定期报告 | 2024-10-02 |
| 2024-09-11 | 389.01 | 未披露 | 定期报告 | 2024-09-11 |
| 2024-09-11 | 86.13 | 0.23 |
更多>>
From April 30, 2024 to July 31, 2024
Issuance of preferred stock for cash
Conversion of preferred stock to common stock
|
2024-07-31 |
| 2024-07-30 | 84.12 | 未披露 | 定期报告 | 2024-07-29 |
| 2024-07-12 | 79.82 | 未披露 |
更多>>
a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value by a ratio of one-for-ten
|
2024-07-16 |
| 2024-07-03 | 798.18 | 未披露 | 定期报告 | 2024-07-02 |
| 2024-06-26 | 788.95 | 未披露 | 定期报告 | 2024-06-25 |
| 2024-05-31 | 737.60 | 0.22 | 定期报告 | 2024-05-29 |
| 2024-05-10 | 688.00 | 未披露 | 定期报告 | 2024-05-09 |
| 2024-07-30 | 688.00 | 0.21 |
更多>>
From April 30, 2023 to April 30, 2024
Issuance of common stock for cash
Issuance of common stock for restricted stock awards
Return of common stock for subscription receivable
|
2024-04-30 |
| 2024-03-25 | 686.68 | 未披露 | 定期报告 | 2024-03-22 |
| 2024-03-25 | 684.94 | 未披露 | 定期报告 | 2024-03-14 |
| 2024-03-25 | 661.88 | 0.12 |
更多>>
From October 31, 2023 to January 31, 2024
Issuance of common stock for cash
Return of common stock for note receivable - related party
|
2024-01-31 |
| 2023-12-15 | 712.07 | 未披露 | 定期报告 | 2023-12-14 |
| 2023-12-15 | 646.97 | 未披露 |
更多>>
Alzamend Neuro, Inc. announced that Alzamend’s board of directors approved a one-for-fifteen reverse stock split of Alzamend’s common stock (“Common Stock”) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on October 31, 2023.
|
2023-10-31 |
| 2023-07-27 | 9694.01 | 未披露 |
更多>>
From April 30, 2022 to April 30, 2023
Issuance of common stock for related party payable
Issuance of common stock for restricted stock awards
Proceeds from stock option exercise
|
2023-04-30 |
| 2023-03-31 | 9694.01 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-15 | 9644.01 | 未披露 | 定期报告 | 2023-03-15 |
| 2023-03-15 | 9642.76 | 未披露 |
更多>>
From October 31, 2022 to January 31, 2023
Issuance of common stock for related party payable
|
2023-01-31 |
| 2022-12-12 | 9642.76 | 未披露 | 定期报告 | 2022-12-12 |
| 2022-12-12 | 9549.43 | 未披露 |
更多>>
From July 31, 2022 to October 31, 2022
Issuance of common stock for restricted stock awards
|
2022-10-31 |
| 2022-07-19 | 9548.18 | 未披露 |
更多>>
From April 30, 2021 to April 30, 2022
Conversion of Series A convertible stock
Issuance of common stock for restricted stock awards
Issuance of common stock & warrants-related party, net
Proceeds from stock option exercise
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million
Issuance of shares of common stock for conversion of debt
|
2022-04-30 |
| 2022-03-15 | 9010.26 | 未披露 |
更多>>
From October 31, 2021 to January 31, 2022
Issuance of shares of common stock for conversion of note
Proceeds from stock option exercise
|
2022-01-31 |
| 2021-12-13 | 8885.04 | 未披露 |
更多>>
From July 31, 2021 to October 31, 2021
Issuance of common stock for restricted stock awards
Proceeds from stock option exercise
|
2021-10-31 |
| 2021-09-13 | 8688.79 | 未披露 |
更多>>
From April 30, 2021 to July 31, 2021
Conversion of Series A convertible stock
Proceeds from sale of common stocks & warrants-related party
Proceeds from stock option exercise
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.46 million
|
2021-07-31 |
| 2021-07-29 | 8530.45 | 未披露 | 定期报告 | 2021-07-20 |
| 2021-06-15 | 8492.95 | 未披露 |
更多>>
1.Common stock offered by company 2,500,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 82,429,525 shares of common stock outstanding as of June 4, 2021
|
2021-06-15 |
From July 31, 2025 to October 31, 2025
Conversion of preferred stock to common stock
From April 30, 2025 to July 31, 2025
Conversion of preferred stock to common stock
a one-for-nine reverse stock split of Alzamend’s common stock
From October 31, 2024 to January 31, 2025
Issuance of common stock for cash, net of issuance costs
From July 31, 2024 to October 31, 2024
Issuance of common stock for cash, net of issuance costs
Issuance of common stock for restricted stock awards
Conversion of preferred stock to common stock
From April 30, 2024 to July 31, 2024
Issuance of preferred stock for cash
Conversion of preferred stock to common stock
a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value by a ratio of one-for-ten
From April 30, 2023 to April 30, 2024
Issuance of common stock for cash
Issuance of common stock for restricted stock awards
Return of common stock for subscription receivable
From October 31, 2023 to January 31, 2024
Issuance of common stock for cash
Return of common stock for note receivable - related party
Alzamend Neuro, Inc. announced that Alzamend’s board of directors approved a one-for-fifteen reverse stock split of Alzamend’s common stock (“Common Stock”) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on October 31, 2023.
From April 30, 2022 to April 30, 2023
Issuance of common stock for related party payable
Issuance of common stock for restricted stock awards
Proceeds from stock option exercise
From October 31, 2022 to January 31, 2023
Issuance of common stock for related party payable
From July 31, 2022 to October 31, 2022
Issuance of common stock for restricted stock awards
From April 30, 2021 to April 30, 2022
Conversion of Series A convertible stock
Issuance of common stock for restricted stock awards
Issuance of common stock & warrants-related party, net
Proceeds from stock option exercise
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million
Issuance of shares of common stock for conversion of debt
From October 31, 2021 to January 31, 2022
Issuance of shares of common stock for conversion of note
Proceeds from stock option exercise
From July 31, 2021 to October 31, 2021
Issuance of common stock for restricted stock awards
Proceeds from stock option exercise
From April 30, 2021 to July 31, 2021
Conversion of Series A convertible stock
Proceeds from sale of common stocks & warrants-related party
Proceeds from stock option exercise
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.46 million
1.Common stock offered by company 2,500,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 82,429,525 shares of common stock outstanding as of June 4, 2021